Download now: Cannabis Cash

Investing in Psychedelic Medicines That Could Treat Alzheimer’s

Written by Jeff Siegel
Posted February 4, 2021

My heart broke when I heard the news…

One of my favorite singers of all time, and one of the nicest guys I’ve ever met, announced that he has Alzheimer’s.

His name is Anthony Benedetto

But you probably know him as Tony Bennett.

Although Bennett had been a household name since the 1950s, I didn’t discover him until the 1980s, when he launched a comeback that appealed to the MTV generation. 

Gen X kids from across the globe were treated to a talent that ultimately turned many of us into jazz fans. 

I was certainly one of them. But it wasn’t until the early 2000s that I got the chance to meet Tony Bennett.

He was playing at a theater where a good friend of mine worked as a sound engineer. I got to watch the sound check before the show, and later, as hundreds of fans stood in a line that wrapped around the building, I had the opportunity to spend a few minutes with Tony.

I’m calling him that because he told me to call him Tony after I addressed him as Mr. Bennett. :)

In any event, I have to tell you that he was one of the nicest, most down-to-earth people I’ve ever met. 

We talked music, food, and family. It was an absolute pleasure.

So when I heard Tony had been stricken with Alzheimer’s, my stomach fell.  

My great-grandmother suffered from Alzheimer’s, and I know just how horrible this disease is. In fact, as an investor, I’ve always been eager to invest in companies that are seeking to find a cure for this terrible disease.

Interestingly, one of the newest potential therapies for Alzheimer’s is one that uses LSD. 

A company called Eleusis is investigating the anti-inflammatory potential of psychedelics, specifically the application of subperceptual doses of LSD in halting the progression of Alzheimer’s disease.

While plenty of folks still equate LSD with hippies and party drugs, the truth is LSD has been studied for decades as a potential treatment for all kinds of mental health and neurodegenerative diseases. 

But only recently has this molecule moved out of the shadows and into FDA clinical trials and Wall Street boardrooms.

This Is a No-Brainer

If you’re a regular reader of these pages, you know I’ve been very bullish on the psychedelics space. 

In fact, I’ve recommended seven psychedelics stocks to members of my Green Chip Stocks community. And they’re all doing very well. In fact, one in particular, a company called MindMed (OTCBB: MMEDF), has thus far delivered us gains in excess of 760%.  

And to be honest, we haven’t even scratched the surface on that one yet. 

For nearly two years now, I’ve immersed myself in this market.

I’ve pored through the research, visited university chemistry labs where researchers are developing all kinds of various psychedelic molecules, and have done dozens of site visits to see this stuff for myself. 

In my nearly 30 years in finance, I can tell you without hesitation that I’ve never seen an industry so full of potential.

When it comes to mental health treatments, neurodegenerative diseases, and brain trauma, there is little on the market today that works effectively.  

Yet the earliest research on these psychedelic medicines is showing success rates that make what’s currently on the market look like snake oil.

Take the research study that Johns Hopkins University did a couple years ago, where researchers showed tremendous success in treating smoking addiction with psilocybin therapy.  

If you’re unfamiliar, psilocybin is the psychedelic compound produced by “magic mushrooms.” And in this Johns Hopkins study, researchers saw an 80% success rate, which is unheard of in the world of addiction treatment. 

The most "effective” smoking cessation therapy on the market today boasts a success rate of about 30%. Hardly a "success," to be sure.

In addition to studies being conducted at Johns Hopkins, there are now about a dozen private and public companies actively conducting, or preparing to conduct, FDA clinical trials using psychedelic compounds to treat everything from anxiety and depression to PTSD and addiction to Alzheimer’s and Parkinson’s.

I’m not saying psychedelics represent a “miracle cure,” but they're about the closest thing I’ve ever seen, which is why I’ve been loading up the boat since 2019.

And you should be too.

Because the bottom line is the psychedelics market is going to make a lot of people very, very rich — but only those who get in now, while these stocks are still trading at tremendous discounts.

You can get access to a list of some of these companies here.

I’ve also put together a short white paper on the psychedelics market, its potential value for investors, and, of course, some of the psychedelics companies that are just crushing it in the space. 

You can check that out here.

To a new way of life and a new generation of wealth...

Jeff Siegel Signature

Jeff Siegel

follow basic@JeffSiegel on Twitter

Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's page.

Hydrogen Fuel Cells: The Downfall of Tesla?